Adaptive radiotherapy boost for prostate and bladder cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional protocol delivers an adaptive radiation boost using a 1.5‑T MR‑Linac to patients with post‑prostatectomy local relapse of prostate cancer or bladder cancer treated with bladder‑conserving radiotherapy. Treatment planning is adjusted using on‑board MRI, with patients attending the clinic about once every two weeks during radiotherapy and returning for follow‑up every three months after adaptive radiotherapy. The study will collect safety and toxicity data, clinical efficacy outcomes, and regular quality‑of‑life questionnaires to determine whether the adaptive boost lowers side effects while maintaining or improving tumor control. Key eligibility includes adults with confirmed urological tumors, ECOG 0–2, no prior radiotherapy in the current field, and no contraindications to MRI or radiotherapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with newly diagnosed or metastatic/recurrent pathologically confirmed urological tumors, clinically assessed as suitable for adaptive radiotherapy;
* Age ≥ 18 years;
* ECOG performance status score 0-2;
* No prior radiotherapy history within the current radiation field;
* No contraindications for MRI scanning;
* No contraindications for radiotherapy.

Exclusion Criteria:

* Patients with contraindications to radiotherapy;
* Patients unable to tolerate MRI or with contraindications to MRI scanning.

Where it's running

• Cancer Hospital, National Cancer Center, CAMS & PUMC
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Ning-Ning Lu, M.D.
• Email: ningninglu09@163.com
• Phone: 861018611804268

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Bladder cancer: test a biomarker-guided plan after neoadjuvant therapy

  This phase 2 study tests a biomarker- and response-guided plan to preserve the bladder in patients with muscle-invasive bladder cancer after neoadjuvant therapy.

  Recruiting Phase 2 Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07908979

• Urinary Cell-Free DNA Test for Urothelial Cancer Origin

  This study tests a urine-based cell-free DNA test to help diagnose urothelial cancer and identify whether it started in the bladder or upper urinary tract in adults.

  Recruiting Ruijin Hospital · Shanghai · NCT07888374

• BL-M07D1: T-bren vs standard platinum chemo for HER2-expressing metastatic urothelial cancer after anti-PD-(L)1 therapy

  This trial tests whether T-bren can help people with HER2-expressing metastatic urothelial cancer who progressed after anti-PD-(L)1 therapy, compared with standard platinum-based chemotherapy.

  Recruiting at 2 sites Phase 3 SystImmune Inc. · Macon, Georgia and 1 other locations · NCT07869836

• Sac-TMT and pembrolizumab with chemoradiation for bladder muscle invasion

  This trial tests whether adding Sac-TMT and pembrolizumab to chemoradiation helps people with muscle-invasive bladder cancer live longer without the cancer growing or returning.

  Recruiting at 10 sites Phase 3 Merck Sharp & Dohme LLC · Kaohsiung City and 9 other locations · NCT07829783

• Personalized 3D Tumoroids from Your Tumor to Test Treatments

  Researchers are using patient tumor tissue and blood to grow personalized 3D, vascularized tumoroids with autologous immune cells to help tailor treatments for kidney, bladder, and prostate cancers.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07820566

• Irreversible Electroporation for Recurrent Pelvic Tumors

  This study tests whether using irreversible electroporation (IRE) is safe and helps control recurrent pelvic tumors in adults who can’t have other local treatments.

  Recruiting Amsterdam UMC, location VUmc · Amsterdam, North Holland · NCT07782164

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.